Lipoprotein metabolism and implications for atherosclerosis risk determination and treatment decisions

Risk Factors in Coronary Artery Disease

Volumn , Issue , 2006, Pages 35-83

  Superko, H Robert ^a   Voros, Szilard ^a   King, Spencer ^a  

^a PIEDMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85034394214     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (260)

1. Ignatowsky IA. Influence de la nourriture animale sur I’organisme des lapins. Arch Med Exp Anat Pathol 1908; 20:1–20.
2. Anitschkow N, Chalatow S. Uber experimentelle cholesterinteatose and ihre beduting fur die entstehung einiger pathologische prozesse. Zentralbl Allg Pathol 1913; 24:1.
3. Aschoff L. Lectures in Pathology. New York: Hueber, 1924.
4. Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis and longevity. Circulation 1966; 34:679–697.
5. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998; 81:13B–17B.
6. Superko HR. What can we learn about dense LDL and lipoprotein particles from clinical trials? Current opinion in lipidology 1996; 7:363–368.
7. Nishina PM, Johnson JP, Naggert JK, Krauss RM. Linkage of atherogenic lipoprotein phenotype to the low-density lipoprotein receptor locus on the short arm of chromosome 19. Proc Natl Acad Sci USA 1992; 89:708–712.
8. Zhao XQ, Kosinski AJS, Barnhart HX, Superko HR, King SB. Prediction of native coronary artery disease progression following PTCA or CABG in the emory angioplasty verus surgery trial. Med Sci Monit 2003; 9:48–54.
9. Chapman MJ. The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development. Curr Med Res Opin 2005; 21:S17–S22.
10. Deckelaum RJ, Olivecrona T, Eisenberg S. Plasma lipoproteins in hyperlipidemia: roles of neutral lipid exchange and lipase. In: Carlson LA, Olsson AG, eds. Treatment of Hyperlipoproteinemia. New York: Raven Press, 1984:85–93.
11. Glomset JA, Janssen ET, Kennedy R, et al. Role of plasma lecithin: cholesterol acyltransferase in the metabolism of high density lipoproteins. J Lipid Res 1966; 7:638–648.
12. Krauss RM. Atherogenicity of triglyceride- rich lipoproteins. Am J Cardiol 1998; 81:13B–17B.
13. Ruggeri RB. Cholesteryl ester transfer protein: pharmacological inhibition for the modulation of plasma cholesterol levels and promising target for the prevention of atherosclerosis. Curr Top Med Chem 2005; 5:257–264.
14. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993; 88:2762–2770.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499–502.
16. Hodis HN, Mack WJ, Dunn M, Liu C, Selzer RH, Krauss RM. Intermediate density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997; 95:2022–2026.
17. Shen MMS, Krauss RM, Lindgren FT, et al. Heterogeneity of serum low density lipoproteins in normal human subjects. J Lipid Res 1981; 22:236–244.
18. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982; 23:97–104.
19. Krauss RM, Blanche PJ. Detection and quantitation of LDL subfractions. Curr Opin Lipidol 1992; 3:377–383.
20. Lindgren FT, Jensen LC, Hatach FT. The isolation and quantitative analysis of serum lipoproteins. In: Nelson GJ, ed. Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism. New York: John Wiley, 1972:181–274.
21. Krauss RM, Burke DJ. Identifcation of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982; 23:97–104.
22. Blanche PJ, Gong EL, Forte TM. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981; 665:408–419.
23. Alaupovic P. Apolipoproteins and lipoproteins. Atherosclerosis 1971; 13:141–145.
24. Gotto MA. High-density lipoproteins: biochemical and metabolic factors. Am J Cardiol 1983; 52:2B–4B.
25. Green PH, Glickman RM. Intestinal lipoprotein metabolism. J Lipid Res 1981; 22:1153–1173.
26. Fruchart JC, Ailhaud G. Recent progress in the study of ApoA-containing lipoprotein particles. Pro Lipid Res 1991; 30:145–150.
27. Cheung MC, Brown BG, Wolf AC, Albers JJ. Altered particle size distribution of apolipoprotein A-I containing lipoproteins in subjects with coronary artery disease. J Lipid Res 1991; 32:383–394.
28. Mihalich A, Magnaghi P, Sessa L, Trubia M, Acquati F, Taramelli R. Genomic structure and organization of kringles type 3 to 10 of the apolipoprotein (a) gene in 6q26-27. Gene 1997; 196:1–8.
29. Scanu AM, Gless GM. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990; 85:1709–1715.
30. Naruszewicze M, Giroux LM, Davignon J. Oxidative modifcation of Lp(a) causes changes in the structure and biological properties of apo (a). Chem Phys Lipids 1994; 68:167–174.
31. Goldstein JL, Brown MS. Atherosclerosis—the low density lipoprotein receptor hypothesis. Metabolism 1977; 26:1257–1275.
32. Tan MH, Sata T, Havel RJ. The significance of lipoprotein lipase in rat skeletal muscles. J Lipid Res 1977; 18:363–370.
33. Breckenridge WC, Alaupovic P, Cox DW, et al. Apoprotein and lipoprotein concentrations in familial apolipoprotein C-II defciency. Atherosclerosis 1982; 44:223–235.
34. Weisgraber KH, Rall SC, Mahley RW. Human E apoprotein heterogeneity. J Biol Chem 1981; 256:9077–9081.
35. Kinnunen PK, Virtanen JA, Vainio P. Lipoprotein lipase and hepatic endothelial lipase: their roles in plasma lipoprotein metabolism. Atheroscler Rev 1983; 11:65–105.
36. Jensen GL, Baly DL, Brannon PM, et al. Synthesis and secretion of lipolytic enzymes by cultured chicken hepatocytes. J Biol Chem 1980; 25:11141–11148.
37. Von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:13–27.
38. Glomset JA, Janssen ET, Kennedy R, et al. Role of plasma lecithin: cholesterol acyltransferase in the metabolism of high density lipoproteins. J Lipid Res 1966; 7:638–648.
39. Khoo JC, Mahoney EM, Witxtum JL. Secretion of lipoprotein lipase by macrophages in culture. J Biol Chem 1981; 256:7105–7108.
40. Santamarina-Fojo S, Brewer HB, Jr. The familial hyperchylomicronemia syndrome. New insights into underlying genetic defects. JAMA 1991; 265:904–908.
41. Gagne C, Brum LD, Julien P, Moorjani S, Lupien PJ. Primary lipoprotein lipase activity deficiency. Clinical investigation of a French Canadian population. Can Med Assoc J 1989; 140:405–411.
42. Santamarina-Fojo S. Genetic dyslipoproetinemias: rote of lipoprotein lipase and apolipoprotein C-II. Curr Opin Lipidol 1992; 3:186–195.
43. Reymer PW, Gagne E, Groenemeyer BE, et al. A lipoprotein lipase mutation (Asn291 Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat Genet 1995; 10:28–34.
44. Collet X, Tall AR, Serajuddin H, et al. Remodeling of HDL by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-1. J Lipid Res 1999; 40:1185–1193.
45. Jahn C, Osborne JC, Schaefer EJ, et al. In vitro activation of the enzyme activity of hepatic lipase by A-II. FEBS Lett 1981; 131:366–368.
46. Zambon A, Brown G, Deeb S, Brunzell J. Hepatic pilase as a focal point for the development and treatment of coronary artery disease. J InvestMed 2001; 49:112–118.
47. Fielding CJ, Shore VG, Fielding PE. A protein cofactor of lecithin: cholesterol acyltransferase. Biochem Biophys Res Commun 1972; 46:1493–1498.
48. Kastner G. Studies on the cofactor requirements for lecithin-cholesterol acyltransferase. Scand J Lab Invest 1974; 33:19–21.
49. Seguret-Mace S, Latta-Mahieu M, Castro G, et al. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypo alpha lipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation 1996; 94:2177–2184.
50. Meiner VL, Cases S, Myers HM, et al. Diruption of the acyl-CoA:cholesterol acyltransferase gene in mice: evidence suggesting multiple cholesterol esterifcation enzymes in mammals. Proc Natl Acad Sci USA 1996; 93:14041–14046.
51. Rudel LL, Lee RG, Parini P. ACAT2 os a target fpr treat, emt pf cprpmaru jeart dosease asspcoated wotj ju[ercjp;esterp;e, ia. Arterioscler Thromb Vasc Biol 2005; 25:1112–1118.
52. Nissen S. Efect of ACAT inhibition on the progression of coronary atherosclerosis: a randomized controlled trial. Am Heart Assoc Late Breaking Clin Trials 2005;15.
53. Barter PJ, Brewer HB, Jr., Chapman JM, Hennekens CH, Rader DJ, Tall AR. Cholesterol ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. ATVB 2003; 23:160–167.
54. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak. Arteriocler Thromb Vasc Biol 1996; 16:831–842.
55. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paroxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7:69–76.
56. Mackness MI, Walker CH. Multiple forms of sheep serum A-esterase activity associated with the high-density lipoprotein. Biochem J 1988; 250:539–545.
57. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modifcation by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104:129–135.
58. Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 1997; 37:2473–2491.
59. Mendez AJ. Cholesterol efflux mediated by apolipoproteirts is an active cellular process distinct from efflux mediated by passive diffusion. J Lipid Res 1997; 38:1807–1821.
60. Domingo N, Mastellone I, Gres S, et al. The endothelial cholesterol efflux is promoted by the high-density lipoprotein anionic peptide factor. Metabolism 2005; 54:1087–1094.
61. Hamon Y, Broccardo C, Chambenoit O, et al. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylerine. Nat Cell Biol 2000; 2:399–406.
62. Kozarsky KF, Donahee MH, Rigotti A, lqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997; 387:414–417.
63. Zhao SP, Wu ZH, Hong SC, Ye HJ, Wu J. Effect of atorvastatin on SR81 expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits. Clin Chim Acta 2005; Sep (Epub).
64. Hirano KI, legami C, Tsujii HL, et al. Probucol enhances the expression of human hepatic scavenger receptor class B tye I, possibly through a species specific mechanism. Arterioscler Thromb vasc Biol 2005; Sep:8 (Epub).
65. Trigatti B, Rayburn H, Vinals M, et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA 1999; 96:9322–9327.
66. Levy RI, Brensike JF, Epstein SE, et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of the NHLBI type II coronary intervention study. Circulation 1984; 69:325–337.
67. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: I. Reduction of incidence of coronary heart disease, and II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251:351–374.
68. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Stduy (4S). Lancet 1994; 349:1383–1389.
69. Shepherd J, Cobbe SM, Isles CG, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM 1995; 333:1301–1307.
70. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEJM 1996; 335:1001–1009.
71. Downs JR, Clearfeld M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279:1615–1622.
72. Superko HR. Did Grandma give you heart disease ? The new battle against coronary artery disease Am J Card 1998; 82:34–46.
73. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction, 22 investigators. Intensive versus moderate lipid lowering with statins afer acute coronary syndromes. N Engl J Med 2004; 350:1495–1504.
74. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425–1435.
75. Pedersen Terje R, Faergeman Ole, Kastelein John JP, et al. The Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study group. High-Dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005; 294:2437–2445.
76. Brown BG, Hillger L, Zhao XQ, Poulin D, Albers JJ. Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS trial. Familial Atherosclerosis Treatment Study. Ann N Y Acad Sci 1995; 748:407–417.
77. Brown GB, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. NEJM 2001; 345:1583–1592.
78. Soria LF, Ludwig EH, Clarke HRG, Vega GL, Grundy SM, McCarthy BJ. Association between a specifc apolipprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 1989; 86:587–591.
79. Innerarity TL. Familial hypobetalipoproteinemia and familial defective apolipoprotein B100: genetic disorders associated with apolipoprotein B. Curr Opin Lipidol 1990; 1:104–109.
80. Winder AF, Owen JS, Pritchard PH, et al. A first British case of fish-eye disease presenting at age 75 years: a double heterozygote for defined and new mutations affecting LCAT structure and expression. J Clin Pathol 1999; 52:228–230.
81. Hirano K, Kachi S, Ushida C, Naito M. Corneal and macular manifestations in a case of deficient lecithin: cholesterol acyltransferase. Jpn J Ophthalmol 2004; 48:82–84.
82. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med 1977; 62:707–714.
83. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. NEJM 1999; 341:410–418.
84. Superko HR, Berneis KK, Williams PT, Rizzo M, Wood PD. Differential effect of Gemfibrozil in Normolipemic subjects with predominantly dense or buoyant low density lipoprotein particles and the effect on postprandial lipemia and Lp(a). Am J Card 2005; November.
85. Frohlich J, Pritchard PH. Analysius of familial hypoalphalipoproteinemia syn. Mol Cell Biochem 1992; 18:141–149.
86. Genest J, Bard JM, Fruchart JC, Ordovas JM, Schaefer EJ. Familial hypoalphalipoproteinemia in premature CAD. Arterioscler Thromb 1993; 13:1728–1737.
87. Vega GL, Grundy SM. Two patterns of LDL metabolism in normotriglyceridemic patients with hypoalphalipoproteinemia. Arterioscler Thromb 1993; 13:579–589.
88. Marcil M, Boucher B, Krimbou L, et al. Severe familial HDL deficiency in French- Canadian kindreds. Arterioscler Thromb Vasc Biol 1995; 15:1015–1024.
89. Franceschini G, Bondioli A, Granata D, et al. Reduced HDL2 levels in myocardial infarction patients without risk factors for atherosclerosis. Atherosclerosis 1987; 68:213–219.
90. Johansson J, Carlson LA, Landow C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991; 11:174–182.
91. Zambon A, Deeb SS, Brown BG, Hokanson JE, Brunzell JD. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid lowering treatment. Circulation 2001; 103:792–798.
92. Reymer PW, Gagne E, Groenemeyer BE, et al. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat Genet 1995; 10:28–34.
93. Ordovas JM, Schaefer EJ, Salem D, et al. Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. NEJM 1986; 314:671–677.
94. Superko HR, Enas EA, Kotha P, Bhat NK, Garrett B. HDL subclass distribution in individuals of Asian Indian descent. The national Asian Indian heart disease project. Prev Cardiol 2004; 8:81–86.
95. Superko HR, High HDLC. Not protective in the presence of homocysteinemia. Am J Card 1997; 79:705–706.
96. Nagano M, Nakamura M, Kobayashi N, Kamata J, Hiramori K. Effort angina in a middle-aged woman with abnormally high levels of serum high-density lipoprotein cholesterol: a case of cholesteryl-ester transfer protein deficiency. Circ J 2005; 69:609–612.
97. Maruyama T, Sakai N, Ishigami M, et al. Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoptoeinemia. Atherosclerosis 2003; 166:177–185.
98. Kinoshita M, Fujita M, Usui S, et al. Scavenger receptor type BI potentiates reverse cholesterol transport system by removing cholesterol ester from HDL. Atherosclerosis 2004; 173:197–202.
99. NCEP ATP-III. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497.
100. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495–506.
101. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52:1544–1568.
102. Kwiterovich PO. Genetics and molecular biology of familial combined hyperlipidemia. Curr Opin Lipidol 1993; 4:133–143.
103. Sniderman A, Shapiro S, Marpole D, Malcolm I, Skinner B, Kwiterovich PO, Jr. The association of coronary Atherosclerosis and Hyperapobetalipoproteinemia (increased protein but normal cholesterol content in human plasma low density lipoprotein). Proc Natl Acad Sci USA 1980; 97:604–608.
104. Williams RR, Hunt SC, Hopkins PN, et al. Familial dyslipidemic hypertension: evidence from 58 utah families for a syndrome present in approximately 15% of patients with essential hypertension. JAMA 1988; 259:3579–3586.
105. Hunt SC, Wu LL, Hopkins PN, et al. Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia (Study of utah patients with familial dyslipidemic hypertension). Arteriosclerosis 1989; 9:335–344.
106. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595–1607.
107. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993; 34:295–308.
108. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, lowdensity lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94:350–356.
109. Superko HR. Beyond LDL-C reduction. Circulation 1996; 94:2351–2354.
110. Nakamura T, Takano H, Umetani K, et al. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005; 181:321–327.
111. Kishi K, Ochiai K, Ohta Y, et al. Highly sensitive cholesterol assay with enzymatic cycling applied to measurement of remnant lipoprotein-cholesterol in serum. Clin Chem 2002; 48:737–741.
112. Hulley SB, Rosenman RH, Bawol RD, et al. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med 1980; 302:1383–1389.
113. Nakamura T, Takano H, Umetani K, et al. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005; 181:321–327.
114. Austin MA. Review: plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 1:11–14.
115. Superko HR, Wood PD, Laughton C, Krauss RM. Low density lipoprotein (LDL) subclass patterns and postprandial lipemia. Arteriosclerosis 1990; 10:826a.
116. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992; 3:189–199.
117. Reaven GM. Why Syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab 2005; 1:9–14.
118. Austin MA, Kamigaki A, Hokanson JE. Low-density lipoprotein particle size is a risk factor for coronary heart disease independent of triglyceride and HDL cholesterol: a meta-analysis of three prospective studies in men. Circulation 1999; 99:1124.
119. Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495–506.
120. Austin MA, Breslow JL, Hennekens CH, et al. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260:1917–1921.
121. Nishina PM, Johnson JP, Naggert JK, et al. Linkage of atherogenic lipoprotein phenotype to the low-density lipoprotein receptor locus on the short arm of chromosome 19. Proc Natl Acad Sci USA 1992; 89:708–712.
122. Rotter JI, Bu X, Cantor R, et al. Multilocus genetic determination of LDL particle size in coronary artery disease families (abstr). Clin Res 1994; 42:16A.
123. Hogue JC, Lamarche B, Gaudet D, et al. Relationship between cholesteryl ester transfer protein and LDL heterogeneity in familial hypercholesterolemia. J Lipid Res 2004; 45:1077–1083.
124. Stampfer MJ, Krauss RM, Blanche PJ, Noll LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276:882–888.
125. Gardner CD, Fortmann SP, Krauss RM. Small low density lipoprotein particles are associated with the incidence of coronary artery disease in men and women. JAMA 1996; 276:875–881.
126. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prespective results from the Quebec cardiovascular study. Circulation 1997; 95:69–75.
127. St. Pierre AC, Cantin B, Dagenais GR, et al. Los-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men. Arterioscler Thromb Vasc Biol 2005; 25:553–559.
128. Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA 2001; 286:1468–1474.
129. Krauss R. Is the size of low-density lipoprotein particles related to the risk of coronary heart disease? JAMA 2002; 287:712–713.
130. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adulats. NEJM 1999; 340:14–22.
131. Mack WJ, LaBree L, Liu C, Selzer RH, Hodis HN. Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography. Atherosclerosis 2000; 150:371–379.
132. Skoglund-Anderson C, Tang R, Bond MG, de Faire U, Hamsten A, Karpe F. LDL particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men. Arterioscler Thromb Vasc Biol 1999; 19:2422–2430.
133. Robert Superko H, McGovern Mark E, Brenda Garrett Elaine Raul. Nicotinic acid has a differential effect on low density lipoprotein subclass distribution in patients classified as LDL pattern A, B, or I. Am J Cardiol 2004; 94:588–594.
134. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512–3517.
135. Krauss RM, Lindgren FT, Wlliams PT, et al. Intermedicate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987; 2:62–65.
136. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic beneft or therapy in the Stanford Coronary Risk Intervention project. Circulation 1996; 94:2146–2153.
137. Williams PT, Superko HR, Haskell WL, et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 2003; 23:314–321.
138. Watts GF, Lewis B, Brunt JNH, et al. Efects on coronary artery disease of lipidlowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet 1992; 339:563–569.
139. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression. Circulation 1999; 99:1959–1964.
140. Kulkarni KR, Garber DW, Marcovina SM, Segrest JP. Quantification of cholesterol in all lipoprotein classes by VAP-II method. J Lipid Res 1994; 35:159–168.
141. Otvas JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992; 38:1632–1638.
142. Superko HR, Schott RJ, Barr C, Raul E. Comparison of traditional and alternative laboratory methods for the determination of lipid measurements, Lp(a) and LDL phenotype. Circulation 2002; 105:14.
143. Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography: particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem 1984; 259:12201–12209.
144. Mao H, Yang T, Gremon PS. A micro fluids device with linear temperature gradient for parallel and combinatorial measurements. J Am Chem Soc 2002; 124:4432–4435.
145. Okazaki M, Usui S, Ishigami M, et al. Identifcation of unique lipoprotein subclasses for visceral obesit by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol 2005; 25:578–584.
146. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human highdensity lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981; 665:408–419.
147. Cheung MC, Albers JJ. Distribution of high density lipoprotein particles with diferent apoprotein composition; particles with A-I and A-II and particles with A-I but not A-II. J Lipid Res 1982; 23:747–753.
148. Dimayuga P, Zhu J, Oguchi S, et al. Reconstituted HDL containing human apolipoprotein A-1 reduces CAM-1 expression and neointima formation following periadventitial cuff-indced carotid injury in apoE null mice. Biochem Biophys Res Commun 1999; 22:465–468.
149. Cheung MC, Wolfbauer G, Brown BG, Albers JJ. Relationship between plasma phospholipid transfer protein activity and HDL subclasses among patients with low HDL and cardiovascular disease. Atherosclerosis 1999; 142:201–205.
150. Johansson J, Carlson LA, Landow C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation wit the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991; 11:174–182.
151. Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987; 113:589–597.
152. Sich D, Saidi Y, Giral P, et al. Hyperalphalipoproteinemia:characterization of a cardioprotective profile associating increased high-density lipoprotein 2 levels and decreased hepatic lipase activity. Metabolism 1998; 47:965–973.
153. Williams PT, Vranizan KM, Austin MA, Krauss RM. Familial correlations wof HDL subclasses based on gradient gel electrophoresis. Arterioscler Thromb 1992; 12:1467–1474.
154. Scanu AM, Gless GM. Lipoprotein(a). Heterogeneity and biological relevance. J Clin Invest 1990; 85:1709–1715.
155. Terres W, Tatsis E, Pfalzer B, Beil U, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995; 91:948–950.
156. Sandkamp M, Funke H, Schelte H, Kohler E, Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chern 1990; 36:20–23.
157. Dahlen GH, Guyton JR, Attar M, et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74:758–765.
158. Budde T, Fechtrup C, Bosenberg E, et al. Plasma lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb 1994; 14:1730–1736.
159. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA 1994; 271:999–1003.
160. Rifai N, Ma J, Sacks FM, et al. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the physicians’ health study. Clin Chem 2004; 50:1364–1371.
161. Luc G, Bard JM, Arveiler D, et al. Lipoprotein(a) as a predictor of coronary heart disease: the PRIME study. Atherosclerosis 2002; 163:377–384.
162. Cantin B, Gagnon F, Moorjani S, et al. Is Lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec cardiovascular study JACC 1998; 31:519–525.
163. Luc G, Bard JM, Arveiler D, et al. Lipoprotein(a) as a predictor of coronary heart disease: the PRIME study. Atherosclerosis 2002; 163:377–384.
164. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37:434–439.
165. Ariyo AA, Thach C, Tracy R. Cardiovascular health study investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003; 349:2108–2115.
166. Koschirisky ML, Beislegel U, Henne-Bruns D, Eaton DL, lawn RM. Apolipoprotein(a) size heterogeneity is related to variable number of repeat sequences in its mRNA. Biochemistry 1990; 29:640–644.
167. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 1997; 17:239–245.
168. Paultre F, Pearson TA, Weil HF, et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 2000; 20:2619–2624.
169. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000; 46:1956–1967.
170. Tate JR, Berg K, Couderc R, et al. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) standardization project for the measurement of lipoprotein(a). Clin Chem Lab Med 1999; 37:949–958.
171. Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol 2003; 14:361–366.
172. Strater R, Becker S, von Eckardstein A, et al. Prospective assessment of risk factors for recurrent stroke during childhood—a 5-year follow-up study. Lancet 2002; 360:1540–1545.
173. Daida H, Lee YJ, Yokoi H, et al. Prevention of restenos after percutaneous transluminal coronary angioplasty by reducing lipoprotein(a) levels with lowdensity lipoprotein apheresis. Am J Card 1994; 73:1037–1040.
174. Shlipak MG, Simon JA, Vittinghof E, et al. Estrogen and Progestin, Lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283:1845–1852.
175. Maher VMG, Brown BG, Marcovina S, Hilger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995; 274:1771–1774.
176. Genest J, Sniderman A, Cianflone K, Teng B, et al. Hyperapobetalipoproteinemia. Plasma lipoprotein responses to oral fat load. Arteriosclerosis 1986; 6:297–304.
177. Kwiterovich PO. HyperapoB: a pleiotropic phenotype characterized by dense lowdensity lipoprotein and associated with coronary artery disease. Clin Chem 1988; 34:B71–B77.
178. Sniderman AD, Wolfson C, Teng B, Franklin FA, Bachorik PS, Kwiterovich PO. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Internal Med 1982; 97:833–839.
179. Lamarche B, Tchernof A, Mauriege P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279:1955–1961.
180. Utermann G. Apolipoprotein E polmorphism in health and disease. Am Heart J 1987; 113:433–440.
181. Gregg RE, Zech LA, Schaefer EJ, Brewer HB. Type III hyperlipoproteineima: defective metabolism of an abnormal apolipoprotein E. Science 1981; 211:584–586.
182. Gregg RE, Zech LA, Schaefer EJ, Stark D, Wilson O, Brewer HB, Jr. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest 1986; 78:815–821.
183. Mahley RW. Atherogenic hyperlipoproteinemia. The cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol. Med Clin N Am 1982; 66:375–400.
184. Lopez-Miranda J, Ordovas JM, Mata P, et al. Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol. J Lipid Res 1994; 35:1965–1975.
185. Dreon DM, Fernstrom HA, Miller B, Krauss RM. Apolipoprotein E isoform phenotype and LDL subclass response to a reduced-fat diet. Arterioscler Thromb Vasc Biol 1995; 15:105–111.
186. Superko HR. The effect of apolipoprotein E isoform difference on postprandial lipoprotein composition in patients matched for triglycerides, LDL-cholesterol and HDL cholesterol. Artery 1991; 18:315–325.
187. Luc G, Bard JM, Arveiler D, et al. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM study. Arterioscler Thromb 1994; 14:1412–1419.
188. Tirot L, Knijff P, Menzel H, Ehnholm C, Nicaud V, Havekes LM. ApoE polymorphism and predisposition to coronary heart disease in youths of diferent european populations. Arterioscler Thromb 1994; 14:1617–1624.
189. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993; 261:921–923.
190. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer Disease. Statement on use of apolipoprotein E testing for alzheimer disease. JAMA 1995; 274:1627–1629.
191. Barter PJ, Brewer HB, Jr., Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23:160–167.
192. Rittershaus CW, Miller DP, Thomas LJ, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20:2106–2112.
193. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000; 406:203–207.
194. Hirano K, Yamashita S, Matsuzawa Y. Pros and cons of inhibitint cholesteryl ester transfer protein. Curr Opin Lipidol 2000; 11:589–596.
195. Brewer HB, Jr., Remaley AT, Neufeld EB, Basso F, Jayce C. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. ATVB 2004; 24:1755–1760.
196. Naveb M, Anantharamaiah GM, Reddy ST, et al. Human apolipoprotein Al mimetic peptides for the treatment of atherosclerosis. Curr opin Investig Drugs 2003; 4:1100–1104.
197. Oram JF. HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol. Arterioscler Thromb Vasc Biol 2003; 23:720–727.
198. Joyce C, Amar MJA, Lambert G, et al. The ATP binding cassette transporter Al (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Nat Acad Sci 2002; 99:407–412.
199. Robert Superko H. The metabolic syndrome and coronary artery disease. In: Fuster V, et al. ed. Hurst’s the Heart. New York: McGraw-Hill, 2004:2127–2141.
200. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110:1245–1250.
201. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among U.S. adults, 1999-2000. JAMA 2002; 288:1723–1727.
202. Dreon DM, Fernstrom H, Miller B, Krauss RM. Low density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEB J 1994; 8:121–126.
203. Dreon DM, Fernstrom HA, Williams PT, Krauss RM. LDL subclass pattern sand lipoprotein response to a low-fat, high-carbohydrate diet in women. Arterioscler Thromb Vasc Biol 1997; 17:7007–7714.
204. Aude YW, Lamas GA, Lopez-Jimenez F, et al. Results of a randomized trial comparing a high fat low carbohydrate diet to the NCEP step 2 diet; effect on LDL cholesterol subclasses. JACC 2001; 37:280A.
205. Williams PT, Krauss RM, Vranizan KM, Albers JJ, Terry RB, Wood PD. Effects of exercise induced weight loss on low density lipoprotein subfractions in healthy men. Arteriosclerosis 1989; 9:623–632.
206. Williams PT, Krauss RM, Vranizan KM, Wood PD. Changes in lipoprotein subfractions during diet-induced and exercise-induced weight loss in moderately overweight men. Circulation 1990; 81:1293–1304.
207. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with diferent LDL subclass patterns. Atherosclerosis 1992; 95:69–76.
208. Robert Superko H, McGovern Mark E, Brenda Garrett Elaine Raul RN. Nicotinic acid has a differential effect on low density lipoprotein subclass distribution in patients classified as LDL pattern, A., B, or I. Am J Card 2004; 94:588–594.
209. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004; 15:659–665.
210. Franceschini G, Lovati MR, Manzoni C, et al. Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. Atherosclerosis 1995; 114:61–71.
211. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the athergenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996; 16:763–772.
212. Vakkilainen J, Steiner G, Ansquer JC, et al. DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003; 107:1733–1741.
213. Cheung MC, Austin MA, Moulin P, Wolf AC, Cryer D, Knopp RH. Effects of pravastatin on apolipoprotein-specifc high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis 1993; 102:107–119.
214. Vega GL, Krauss RM, Grundy SM. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 1990; 227:81–94.
215. Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Chiesa G, Sirtori CR. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia. J Lab Clin Med Sep 1989; 114:250–259.
216. Krauss RM, Isaacsohn J, Hunninghake D, et al. Changes in atherogenic lipoprotein fractions with simvastatin in patients with hypertriglyceridemia. Circulation 1999; 100:1–470.
217. Superko HR, Krauss RM, DiRicco C. Effect of HMGCoA reductase inhibitor (fluvastatin) on LDL peak particle diameter. Am J Cardiol 1997; 80:78–81.
218. Superko HR, Raul E, Davis V, Aron C. Atorvastatin and LDL subclass distribution. JACC 2001; 37:248A.
219. Ikejiri A, Hirano T, Murayama S, et al. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 2004; 53:1113–1117.
220. Rittershaus CW, Miller DP, Thomas LJ, et al. Vaccine-Induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. ATVB 2000;2106–2112.
221. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000; 406:203–207.
222. Huang Z, Inazu A, Nohara A, Higashikata T, Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond) 2002; 103:587–594.
223. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesterylester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vase Biol 2004; 24:490–497.
224. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350:1505–1515.
225. Brown BG, Zambon A, Poulin D, et al. Use of niacin, statins, and resins in patients with combined hyperlipidemia. Am J Cardiol 1998; 81:52B–59B.
226. O’Keefe JH, Jr., Harris WS, Nelson J, Windsor SL. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol 1995; 76:480–484.
227. Superko HR, Krauss RM. Differential effect on HDL of niacin and resin in LDL subclass pattern A and B subjects. Circulation 1993; 88:1–386.
228. Superko HR, Krauss RM. LDL subclass distribution change in familial combined hyperlipidemia patients following Gemfibrozil and Niacin treatment. JACC 1997; 29:46A.
229. Miller NE. Effects of adrenoceptor-blocking drugs on plasma lipoprotein concentrations. Am J Card 1987; 60:17–23.
230. Superko HR, Wood PD, Krauss RM. Effect of alpha-and selective beta blockade for hypertension control on plasma lipoproteins, apoproteins, lipoprotein subclasses, and postprandial lipemia. Am J Med 1989; 1:26–31.
231. Superko HR, Krauss RM, Haskell WL. Stanford coronary risk intervention project investigators. Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. Atherosclerosis 1993; 101:1–8.
232. Krauss RM, Burkman RT, Jr. The metabolic impact of oral contraceptives. Am J Obstet Gynecol 1992; 167:1177–1184.
233. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. NEJM 1997; 336:1769–1775.
234. Superko HR, Blanche P, Holl L, Orr J, Shoenfeld MJ, Krauss RM. Reduction of plasma LDL and apo B levels with combined estrogenCprogestin therapy in postmenopausal women is greater in women with dense rather than buoyant LDL. Circulation 1998; 98:1–7.
235. Seguret-Mace S, Latta-Mahieu M, Castro G, et al. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation 1996; 94:2177–2184.
236. Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, Ryan U. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 2003; 169:113–120.
237. Gaofu Q, Jun L, Xiuyun Z, Wentao L, Jie W, Jingjing L. Antibody against cholesteryl ester transfer protein (CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model. Life Sci 2005; 77:2690–2702.
238. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein Al. Nature 1991; 353:265–267.
239. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 2001; 103:3047–3050.
240. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292–2300.
241. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterialwall thickness andmajor risk factors: the Atherosclerosis Risk in Communities (ARIC) study, 1987–1993. AmJ Epidemiol 1997; 146:483–494.
242. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128:262–269.
243. Cai JM, Hatsukami TS, Ferguson MS, Small R, Polissar NL, Yuan C. Classifcation of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation 2002; 106:1368–1373.
244. Chun Yuan, Shao-xiong Zhang, Nayak L, et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 2002; 105:181–185.
245. Yuan C, Kerwin WS, Ferguson MS, et al. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J Magn Reson Imaging 2002; 15:62–67.
246. Brent A, French Zequan Yang, Berr Stuart S, Kramer CM. Of mice and men.and broken hearts. Circulation 2001; 104:110.
247. Sirol M, Fuster V, Badimon JJ, et al. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation 2005; 112:1594–1600.
248. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 2001; 103:415–422.
249. Yong Kim W, Stuber Matthias, Börnert Peter, Kissinger Kraig V, Manning Warren J, Botnar René M. Three-dmensional black-blood cardiac magnetic resonance coronary vessel wall imaging detects positive arterial remodeling in patients with nonsignificant coronary artery disease. Circulation 2002; 106:296–299.
250. Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin, C and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol 2005; 46:166–172.
251. LaMonte MJ, FitzGerald SJ, Church TS, et al. Coronary artery calcium score and coronary heart disease events in a large cohort of asymptomatic men and women. Am J Epidemiol 2005; 162:421–429.
252. MoJlet NR, Cademartiri F, van Mieghem CA, et al. High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation 2005; 112:2318–2323.
253. Leber AW, Knez A, von Ziegler F, et al. Quantification of obstructive and nonobstructive coronary lesions by 64-slice computed tomography: a comparative study with quantitative coronary angiography and intravascular ultrasound. J Am Coll Cardiol 2005; 46:147–154.
254. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106:2055–2060.
255. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512–3517.
256. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001; 104:249–252.
257. Corti R, Fuster V, Fayad ZA, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002; 106:2884–2887.
258. Corti R, Fuster V, Fayad ZA, et al. Effects of aggressive versus conventional lipidlowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005; 46:106–112.
259. Zhao XQ, Yuan C, Hatsukami TS, et al. Effects of prolonged intensive lipidlowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 2001; 21:1623–1629.
260. Superko HR, Hecht H. Metabolic disorders contributing to subclinical coronary atherosclerosis in patients with coronary calcification. Am J Card 2001; 88:260–264.